Interleukin-6 gene transfer reverses body weight gain and fatty liver in obese mice

Yongjie Ma, Mingming Gao, Hao Sun, Dexi Liu*

Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, GA 30602, USA

A R T I C L E   I N F O

Article history:
Received 9 October 2014
Received in revised form 16 January 2015
Accepted 21 January 2015
Available online 4 February 2015

Keywords:
IL-6
Obesity
Weight loss
Insulin resistance
Energy expenditure

A B S T R A C T

Interleukin-6 (IL-6) is a multifunctional protein and has a major influence on energy metabolism. The current study was designed to assess the therapeutic effect of overexpression of IL-6 gene through gene transfer on high fat diet-induced obese mice. Hydrodynamic delivery of 1 μg pLIVE-IL6 plasmid per mouse into C57BL/6 obese mice resulted in peak level at 10 ng/ml of circulating IL-6 1 day after gene transfer and above 1 ng/ml thereafter for a period of 6 weeks. Persistent IL-6 gene expression did not affect food intake but induced a significant reduction in body weight and improved obesity-associated hepatic steatosis. IL-6 gene delivery enhanced thermogenic gene expression and elevated protein levels of phosphorylated STAT3, PGC1α, and UCP1 in brown adipose tissue. IL-6 overexpression elevated mRNA levels of lipolysis genes, triggered phosphorylation of STAT3, AMPK, and ACC, and increased expression of genes involved in fatty acid oxidation in skeletal muscle. IL-6 did not affect macrophage infiltration but maintained the M2 macrophage population in adipose tissue. Collectively, these results suggest that overexpression of the IL-6 gene by hydrodynamic gene delivery induces weight loss and alleviates obesity-induced fatty liver and insulin resistance, supporting the notion that gene transfer is a valid approach in managing obesity epidemics.

© 2015 Elsevier B.V. All rights reserved.

1. Introduction

Interleukin-6 (IL-6), produced by immune and non-immune cells, is a multifunctional cytokine. IL-6 is commonly known as a pro-inflammatory cytokine that regulates immune response and acute immune response. More recent studies have shown that IL-6 has an anti-inflammatory activity as it increases the production of IL-10, IL-1 receptor antagonist (IL-1ra), and soluble TNF-receptors [1–3]. In addition to modulating the immune system, IL-6 has also attracted particular attention for its pivotal role in regulating energy expenditure, body composition and peripheral lipid metabolism [4–6].

The effects of IL-6 on nutrient homeostasis and obesity remain controversial and unresolved. IL-6 is generally considered an obesity-related inflammatory factor and mediator for insulin resistance as elevated circulating IL-6 is correlated with adiposity and insulin resistance in humans [7–9]. However, substantial evidence suggests that IL-6 exerts a beneficial influence in this context. Physical exercise promotes secretion of IL-6 from skeletal muscle and the blood concentration of IL-6 increases about 100-fold, improving insulin sensitivity [10,11], while IL-6 knockout mice developed obesity, systemic insulin resistance and inflammation [4,12], which could be partially reversed by intra-cerebroventricular injection of the IL-6 protein [4]. Meanwhile, direct delivery of adeno-associated viral vectors containing the IL-6 gene into the rat hypothalamus or mice carrying the human IL-6 gene suppressed weight gain and visceral adiposity [13,14], indicating that IL-6 exerts anti-obesity effects in rodents. Moreover, short-term intracerebroventricular injections of the recombinant IL-6 protein and a peripheral increase in IL-6 gene expression induced weight loss and improved insulin sensitivity in mice [15,16]. Although these studies support the potential application of IL-6 in fighting obesity, the systemic effects of prolonged elevation of IL-6 level in obese mice remain unknown.

Here we preserve sustained IL-6 expression in obese mice by hydrodynamic gene delivery and demonstrate that long-term maintenance of IL-6 levels significantly induced weight loss in obese mice by enhancing lipolysis and energy metabolism, resulting in improved insulin sensitivity and maintenance of glucose homeostasis as well as a reduction in fat accumulation in the liver. IL-6 gene transfer did not affect macrophage infiltration, but countered the obesity-related inflammatory signal by enhancing the expression of M2 macrophage gene markers and related anti-inflammatory factor genes. Our results indicate the long-term beneficial effects of IL-6 elevation on obesity and suggest the potential application of IL-6 gene transfer as a means of controlling obesity and obesity-related metabolic disorders.

* Corresponding author at: Department of Pharmaceutical and Biomedical Science, University of Georgia College of Pharmacy, 450 Pharmacy South, 250 West Green Street, Athens, GA 30602, USA. Tel.: +1 706 542 7385; fax: +1 706 542 5358.
E-mail address: dliu@uga.edu (D. Liu).

http://dx.doi.org/10.1016/j.bbadis.2015.01.017
0925-4439/© 2015 Elsevier B.V. All rights reserved.
2. Methods and materials

2.1. Plasmid construction

A mouse IL-6 open reading fragment was obtained from OriGene (Rockville, MD) and reconstructed into a pLIVE plasmid vector (Mirus Bio, Madison, WI) at the Nhel and XhoI cutting sites. The insertion in the new plasmid (pLIVE-IL6) was confirmed using DNA sequencing. The pLIVE-IL6 and empty plasmids were purified using CsCl-ethidium bromide density-gradient ultracentrifugation and kept in saline (0.9% sodium chloride). Purity of the plasmids was verified with absorbance ratio at 260 and 280 nm and by 1% agarose gel electrophoresis.

2.2. Animal treatment

C57BL/6 mice (male, 10–week old) were purchased from Charles River Laboratories (Wilmington, MA) and housed under standard conditions with a 12 h light-dark cycle. All procedures performed on animals were approved by the Institutional Animal Care and Use Committee at the University of Georgia, Athens, Georgia. Obese mice (50 ± 2 g) were developed by feeding animals for 2 weeks with high fat diet (HFD) (60% kJ fat, 20% kJ carbohydrate, 20% kJ protein, Bioserv, Frenchtown, NJ). Regular mice were fed with a standard laboratory chow diet (20% kJ fat, 60% kJ carbohydrate, 20% kJ protein, LabDiet, St Louis, MO). Food consumption was determined by measuring the difference between the amount provided and the amount left every three days. Food intake per mouse was calculated based on the amount consumed divided by time and the number of mice per cage. The procedure for hydrodynamic gene delivery in obese mice was performed according to an established procedure [17,18] with some modifications. Briefly, an appropriate volume of saline solution (equivalent to 8% lean mass of an obese mouse) containing 1 μg pLIVE-IL6 or empty plasmid was injected through the tail vein within 5–8 s. Mice were continually fed an HFD for 6 months. The body weight of each mouse was measured on an electronic balance, and body composition was analyzed using EchoMRI-100 (Echo Medical Systems, Houston, TX) once per week. The same procedures were also performed on age-matched male mice with Chow feeding. Blood was collected at the desired time points was measured using a specially designed Thermo-couple Meter from Kent Scientific (Torrington, CT).

2.3. Evaluation of glucose homeostasis and insulin sensitivity

Insulin concentrations were determined using a Mercodia Insulin ELISA kit from Merckodia Developing Diagnostics (Winston Salem, NC) following the provided protocol. For the glucose tolerance test (ITT), mice were injected intraperitoneally with glucose at 1.5 g/kg body weight after 6 h fasting. Blood samples were taken at varying time points and glucose concentrations were determined using glucose test strips and TUREtrack glucose meters from Nipro Diagnostics Inc. (Fort Lauderdale, FL). For the insulin tolerance test (ITT), mice fasted for 4 h and blood glucose levels were measured after an intraperitoneal injection of insulin (0.75 U/kg) from Eli Lilly (Indianapolis, IN). HOMA-IR values were calculated based on the formula: (fasting insulin [μU/mL] × fasting glucose [mmol/L])/22.5.

2.4. Histochmical and Oil Red O analysis

After mice were sacrificed, the liver, WAT, and BAT were collected, fixed in 10% formalin and embedded in paraffin. Hematoxylin and eosin (H&E) staining was performed using tissue sections at a thickness of 6 μm. Frozen liver sections (8 μm) were stained with 0.2% Oil Red O reagent (Electron Microscopy Sciences, Hatfield, PA) in 60% isopropanol for 15 min, washed three times with phosphate buffered saline and counter-stained with hematoxylin for 1 min. A microscopic examination was performed and photographs were taken under a regular light microscope.

2.5. Blood and hepatic lipid analysis

A quantitative determination of liver lipids was performed according to an established procedure [19,20]. Briefly, liver tissues (100–200 mg) were homogenized in phosphate buffered saline (1 ml), mixed with 5 ml of organic solvent (chloroform = 2:1, vol/vol) and incubated overnight at 4 °C. The mixture was centrifuged and the organic phase collected. The collected fraction was dried and lipids were re-dissolved in 1% Triton X-100. The amounts of cholesterol, triglyceride (Thermo Fisher Scientific Inc., Waltham, MA) and free fatty acids (Wako Bioproducts, Richmond, VA) were determined following the manufacturers’ instructions. The same kits were also used for blood lipid analysis.

2.6. Gene expression analysis by real time PCR

Total RNA was isolated from mouse livers, the pancreas, WAT and BAT using the TRIZOL reagent (Life Technologies, Grand Island, NY) or RNaseq Lipid Tissue Mini Kit (QIAGEN, Valencia, CA) according to the manufacture's instructions. For the glucose tolerance test, the same kits were also used for blood lipid analysis.

Table 1

<table>
<thead>
<tr>
<th>Name</th>
<th>Forward sequence</th>
<th>Reverse sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gimap1</td>
<td>GCAACGACGCTGAGAG</td>
<td>GTGATCATGACGAGTC</td>
</tr>
<tr>
<td>Gapdh</td>
<td>GCCATGCGCTGACGCT</td>
<td>GTGGGAGATTACGGCA</td>
</tr>
<tr>
<td>Pparγ1</td>
<td>GGAAGACCGCACTTCTCTC</td>
<td>GTACCATCGAACATCAG</td>
</tr>
<tr>
<td>Pparγ2</td>
<td>TGGCCGATGATGATGATG</td>
<td>GAGACTCGAGATGATGATG</td>
</tr>
<tr>
<td>Cd36</td>
<td>CUGGAAAGGACGAGGAGGAG</td>
<td>CTGAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Pohp4</td>
<td>AGTTGACGGTATTTCGAG</td>
<td>TCTCGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Mgst1</td>
<td>TGCTCAGTGTTTGTTTACTAA</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Pparα</td>
<td>TTGCTGAAATCTTGGGAAAACA</td>
<td>AATCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Acox1</td>
<td>CGGCAAACTCTACAGGACGAG</td>
<td>AAATCCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Cpt1a</td>
<td>CTCGAGTGATGATGATGATG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Cpt1b</td>
<td>GCCTGCTTCTTATTGCTGCT</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Sreb1c</td>
<td>CGCTTCGTTGACGAGGACGAG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Fas</td>
<td>GAGAATGCAGGCACTGCTTCT</td>
<td>CTGCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Scd-1</td>
<td>TCTCTTACACGCACTTCTTCT</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Cyp7a1</td>
<td>AAGCCGTTGACGAGGACGAG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Ihmg Cr</td>
<td>TGGCTAGTGATGATGATGATG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Pepck</td>
<td>AACCTGCTCAGGACGAGGACGAG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Gspase</td>
<td>CGGCTGCTCTTGGGACGAGGACGAG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Insulin1</td>
<td>CCTCTTCGTTGACGAGGACGAG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Insulin2</td>
<td>CCTCTTCGTTGACGAGGACGAG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Hsl</td>
<td>GAGGATGTGACGAGGACGAG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Agtl</td>
<td>CACCGCCACTCAGCTACTCATGG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Ucp1</td>
<td>AGGTCTCCGATGATGATGATG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Ucp2</td>
<td>GCCCTGCTTCTATCAGCTTCT</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Ucp3</td>
<td>ATGGATTCTCGTTGTCCTGCT</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Pgc-1a</td>
<td>GAATTGCTGATGATGATGATG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Pgc-1h</td>
<td>TTTGAGATGCTGATGATGATG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Dio2</td>
<td>AATATTGCCGAGGAGGAGGAG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Cidea</td>
<td>AATCGGATGCTGATGATGATG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Floyd</td>
<td>CTCTCGTCTGATGATGATG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>F4/80</td>
<td>CGGGGCCGCTGCTGCTGCTG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Cd68</td>
<td>CCTCAGTGCTGCTGCTGCTG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Cd11b</td>
<td>AGTGAGTCTGCTGCTGCTG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Cd11c</td>
<td>AGTGAGTCTGCTGCTGCTG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Mep-1</td>
<td>AGTGAGTCTGCTGCTGCTG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Tnfa</td>
<td>CCTACGTCTGCTGCTGCTG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Il-1β</td>
<td>GCCAGACTGCTGCTGCTGCTG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Cift3</td>
<td>TACCTCAGTGCTGCTGCTG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Cift2</td>
<td>CAGCTCTCAGTGCTGCTGCTG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Il-10</td>
<td>CCTCTCAGTGCTGCTGCTG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Il-4</td>
<td>CGGAACCCTGCTGCTG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Il-4α</td>
<td>TCTGCGAGTCTGCTGCTG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Il-13</td>
<td>CTTGCTGCTGCTGCTGCTG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Acad1</td>
<td>CTTCAGTGCTGCTGCTG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
<tr>
<td>Gapdh</td>
<td>AGTGAGTCTGCTGCTGCTG</td>
<td>TCTCAGGTTTTCGAGAG</td>
</tr>
</tbody>
</table>

For the glucose tolerance test, the same kits were also used for blood lipid analysis.
manufacturers’ protocols. One microgram of total RNA was employed for the first strand cDNA synthesis using a First-strand cDNA Synthesis System from OriGene (Rockville, MD). Real time PCR was performed in an ABI StepOne Plus Real Time PCR system (Foster City, CA) using PerfeCTa® SYBR® Green FastMix (Quanta BioSciences, Gaithersburg, MD) as the indicator. PCR was carried out for 40 cycles at 95 °C for 15 s and 60 °C for 1 min. The data were analyzed using the ΔΔCt method and normalized to internal control of GAPDH mRNA. Primers were synthesized at Sigma (St. Louis, MO). All primer sequences employed are summarized in Table 1. Melting curve analysis of all real-time PCR products was conducted and showed a single DNA duplex.

2.7. Western Blotting analysis

Tissue samples were homogenized on ice using a Tissue Tearor in 1 ml lysis buffer (25 mM Tris–HCl, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, pH 7.6) with a protease inhibitor cocktail from Millipore (Billerica, MA). The tissue homogenates were centrifuged at 12,000 rpm for 10 min and total proteins were extracted from the supernatant. Fifty micrograms of proteins was separated on a 7.5% SDS-polyacrylamide gel and transferred onto a polyvinylidene difluoride membrane using a Bio-Rad Mini-Blot transfer apparatus (Richmond, CA). Membranes were blocked in a Tris-buffered solution containing 5% non-fat milk for 1 h. Immunoblotting was performed at 4 °C overnight with shaking using antibodies against UCP1, PGC1α from Abcam (Cambridge, MA), STAT3, p-STAT3, AMPK, p-AMPK, ACC, p-ACC from Cell Signaling (Boston, MA) or GAPDH from Santa Cruz Biotechnology (Santa Cruz, CA), respectively. After washing, the membranes were incubated in a 1:3000 dilution of a secondary antibody at room temperature for 1 h in Tris-buffered solution containing 0.5% of Tween-20. Protein bands were visualized using Pierce ECL Western Blotting substrate (Rockford, IL).

2.8. Statistical analysis

A statistical analysis was performed using the Student’s t test. All data are reported as mean ± standard deviation (SD) with statistical significance set at P < 0.05.

3. Results

3.1. Prolonged Il-6 gene expression induces weight loss in C57BL/6 obese mice

The level and time-dependent Il-6 gene expression after hydrodynamic delivery of 1 μg of pLIVE-IL6 plasmids was examined in obese mice fed an HFD. Results in Fig. 1A show that blood concentration of IL-6 protein reached the peak level (~10 ng/ml) 1 day after gene transfer and declined slightly with time. Six weeks after gene transfer, circulating IL-6 level remained at approximately 1 ng/ml, 50-fold higher than that of control mice (~20 pg/ml) injected with empty plasmid. PCR analysis revealed the highest level of Il-6 gene expression in the liver, 120-fold higher than the background level in control animals (Fig. 1B). A slight increase of mRNA level was also seen in BAT and skeletal muscle. Blood chemistry tests showed no increase of serum concentrations of AST and ALT in animals with Il-6 gene transfer at the end of 6-week experiment (Fig. 1C). These results prove that Il-6 gene expression can be successfully achieved and sustained after hydrodynamic gene delivery.

The therapeutic effect of prolonged Il-6 gene expression on obese mice is shown in Fig. 1D and E. A slight decrease in body weight was seen immediately after plasmid injection in both treated and control animals due to effect of the procedure. However, animals injected with pLIVE-IL6 plasmid continued to lose weight and eventually reached a steady state with an average body weight of 38 g in 6 weeks, losing an average of 12 g of their initial body weight of 50 ± 2 g. In contrast, control mice regained the body weight initially lost and gained an additional 2 g by the end of the experiment. The analysis of body composition by magnetic resonance imaging (MRI) revealed that weight loss in animals with Il-6 gene transfer is fully correlated to the time-dependent decrease in fat mass (Fig. 1F), not lean mass (Fig. 1G). No change in fat and lean mass was observed in control animals. Moreover, the loss of body weight is not correlated to food intake (Fig. 1H). In addition, body fat reduction was further determined by weighing fat pads. Results in Fig. 2A and B show that Il-6 gene transfer significantly reduced the size of fat pads including subcutaneous (subWAT), epididymal (epiWAT) and retroperitoneal (retroWAT) adipose tissues in obese
mice by ~0.9, ~1.2 and ~1.0 g, respectively. Accordingly, H&E staining of adipocytes in subWAT, epiWAT and retroWAT showed reduced size of adipocytes (Fig. 2C), which was also confirmed by quantification analysis using an imaging system (Fig. 2D).

To examine whether IL-6 gene transfer only affects fat mass, we performed the same set of experiments in age-matched chow-fed mice. The expression of IL-6 gene after hydrodynamic gene delivery slightly reduced body weight of normal mice by 2.5 g due to reduced fat mass, but not lean mass (Fig. 3A, C and D). Again, IL-6 gene transfer did not affect food intake in mice fed a regular chow (Fig. 3B). Taken together, these data demonstrate that prolonged IL-6 gene expression reduces body weight and fat mass without affecting food intake.

3.2. Sustained IL-6 level alleviates hepatic steatosis in obese mice

Obese mice displayed an extensive vacuolation in H&E stained liver section (Fig. 4A), indicating severe fat accumulation in the liver. IL-6 gene transfer dramatically reduced fat accumulation in the liver, as evidenced by the recovered normal liver structure (Fig. 4A) and fewer lipid droplets stained by Oil Red O (Fig. 4B). Consistent with these results, IL-6 gene transfer significantly reduced hepatic triglyceride, total cholesterol and free fatty acid levels in obese animals (Fig. 4C–E). IL-6 gene transfer also reduced blood concentrations of free fatty acid, but not triglyceride levels (Fig. 4F–H).

A real time PCR analysis was carried out to evaluate the effect of IL-6 gene transfer on the expression of genes involved in hepatic fat accumulation. Fig. 5A shows that IL-6 gene transfer markedly suppressed mRNA levels of peroxisome proliferator-activated receptor gamma (Pparγ1) (42%), Pparγ2 (83%), and their target genes, including Cd36 (71%), fatty acid binding protein 4 (Fabp4, 46%), and monoacylglycerol O-acyltransferase 1 (Mgat1, 99%). At the end of the 6-week experiment, IL-6 did not affect Pparα and its target genes including carnitine palmitoyl-transferase I (Cpt1) and peroxisomal acyl-coenzyme A oxidase 1 (Acox1) (Fig. 5B). IL-6 also did not significantly affect hepatic lipogenic genes with the exception of reducing fatty acid synthase (Fas) gene expression by 46%. In regard to cholesterol metabolism, IL-6 enhanced 3-hydroxy-3-methylglutaryl coenzyme A reductase (Hmgcr) gene expression by 2 fold and increased cholesterol 7 α-hydroxylase (Cyp7a1) gene expression by 4.3 fold (Fig. 5C). Collectively, these data demonstrate that prolonged IL-6 gene expression alleviates obesity-associated fatty liver.

Fig. 2. IL-6 reduced fat tissues depots and the size of adipocytes in obese mice. Obese mice were sacrificed at the end of the 6-week after gene transfer and different fat pads were collected and weight determined. Tissues were fixed in 10% neutral buffered formalin. H&E staining was performed to show the morphology of adipose tissues. (A) Appearance of subcutaneous (subWAT), epididymal (epiWAT) and retroperitoneal (retroWAT) fat tissues collected from obese mice; (B) Weight of fat pads in (A); (C) Representative images of H&E staining of subWAT, epiWAT and retroWAT (100×); and (D) Average diameter of adipocytes in different fat pads (calculated from 200 adipocytes from 4 separate slides). Results represent mean ± SD. *P < 0.05, **P < 0.01, comparing to control obese mice injected with pLIVE empty plasmid.
3.3. Elevation of IL-6 level improves insulin sensitivity and glucose homeostasis in obese mice

To address the impact of IL-6 gene transfer on insulin sensitivity and glucose homeostasis, we monitored blood insulin levels and pancreatic insulin gene expression. IL-6 dramatically suppressed obesity-induced hyperinsulinemia by 78% (Fig. 6D). Accordingly, pancreatic mRNA levels of Insulin1 and Insulin2 genes were markedly lower in mice with IL-6 gene transfer compared to control obese animals (Fig. 6E, F). In the meantime, a glucose tolerance test (Fig. 6A) and calculated area under the curve (AUC, Fig. 6B) revealed a lower peak level and much higher clearance rate of intra-peritoneally injected glucose in animals with IL-6 gene transfer. Moreover, mice with IL-6 gene transfer were more sensitive to insulin than control obese mice when tested using an insulin tolerance test (Fig. 6C), and improved insulin sensitivity was also reflected by reduction in calculated HOMA-IR (Fig. 6G), the assessment index of insulin resistance. Taken together, these data indicate that IL-6 gene transfer improves insulin sensitivity and glucose homeostasis in obese mice.

3.4. IL-6 treatment enhances lipolysis and stimulates thermogenesis in obese mice

IL-6 has been shown to increase energy expenditure by stimulating the function of brown adipose tissue (BAT) [13,21]. Result in Fig. 5A shows that IL-6 increased the body temperature by 0.8 °C 1 day after gene transfer followed by a gradual decline thereafter, suggesting enhanced energy expenditure. H&E stained BAT showed a dramatic reduction in lipid droplets and the density of vacuole type structures (Fig. 7A). Data in Fig. 7B show that IL-6 increased the expression of genes involved in lipid utilization and thermogenesis in BAT including the fatty acid transporter gene (Cd36, ~1.6-fold), hormone-sensitive lipase (Hsl, ~2.2-fold), and adipose triglyceride lipase (Atgl, ~5.4-fold). IL-6 also elevated the expression of genes responsible for fatty acid oxidation (Cpt1, ~2.0-fold) and thermogenesis in BAT, as reflected by increased thermogenic genes including Ucp1 (~1.9-fold), Ucp2 (~1.6-fold), Ucp3 (~4.8-fold), Pgc1 (~2.6-fold), Cidea (~2.6-fold), and Elovl3 (~3.5-fold). Moreover, a Western Blotting analysis (Fig. 7C) confirmed that IL-6 significantly activated its signaling molecule of STAT3 in BAT, as evidenced by a 3-fold increase in the ratio of the p-STAT3 to STAT3 (Fig. 7D). Consequently, higher IL-6 levels enhanced protein levels of PGC1α and UCP1, two key effectors in thermogenesis (Fig. 7E). In addition, IL-6 gene transfer increased the expression of Hsl, Atg, Cpt1 in subcutaneous WAT (Fig. 8A–B).

Skeletal muscle is another tissue capable of utilizing fatty acids. As shown in Fig. 9A and B, IL-6 stimulated phosphorylation of STAT3 in skeletal muscle by 1.6-fold, indicating its potential function in muscle. We found that IL-6 stimulated the phosphorylation of AMPK, a master regulator for fatty acid oxidation [22], and its downstream target acetyl-CoA carboxylase (ACC) in skeletal muscle (Fig. 9A, C and D). Results shown in Fig. S2 demonstrate that mRNA levels of peroxisomal acyl-CoA oxidase 1 (Acox1), Cpt1a, Cpt1b and long-chain specific acyl-CoA dehydrogenase (Acadl) gene were significantly increased in animals with IL-6 gene transfer. In the meantime, the mRNA levels of Ucp3 and Pgc1α were also elevated by ~2.0-fold and ~3.0-fold, respectively, suggesting that IL-6 has enhanced lipid utilization in skeletal muscle.

3.5. Sustained IL-6 treatment did not affect macrophage infiltration, but increased the M2 macrophage population in adipose tissue and liver

Finally, we examined the effect of IL-6 gene transfer on macrophage infiltration and inflammatory response in BAT, WAT and liver tissue (Fig. 10). IL-6 did not reduce existing macrophages, although it did dramatically reduce chemo-attractant Mcp-1 gene expression in all tested
tissues. However, IL-6 gene transfer significantly increased expression of M2 macrophage marker genes such as Cd163 and Cd206 in BAT, subWAT and the liver. In the meantime, IL-6 evidently enhanced the transcript levels of anti-inflammatory Il-10 and M2-related factor Il-4, Il-13 and their receptors. Taken together, these results suggest that IL-6 counterbalances obesity-associated pro-inflammatory factors.

4. Discussion

In the current study, we examined the long-term effects of IL-6 gene transfer on obesity and related metabolic syndromes and explored the potential molecular mechanisms. Our results show that sustained IL-6 gene expression can be achieved in obese mice via the method of hydrodynamic gene delivery, resulting in reduction of body weight and fat mass (Figs. 1 and 2), alleviation of hepatic steatosis (Fig. 4), and improvement of glucose homeostasis (Fig. 6). These beneficial effects were associated with elevated lipid mobilization in WAT and enhanced thermogenesis in BAT (Figs. 7, 8). IL-6 did not reduce obesity-related macrophage infiltration, but significantly increased expression of M2 macrophage markers and anti-inflammatory factor genes (Fig. 10).

Reduction in body weight by hydrodynamic IL-6 gene transfer is not caused by reduction in food intake (Fig. 1H). This conclusion is in agreement with previous study where adeno-associated viral vector was used to deliver the IL-6 gene into the hypothalamus in rats [13]. It was shown that AAV-mediated IL-6 gene transfer suppressed weight gain of animals and the visceral adiposity but did not affect food intake in a period of 5 weeks. However, intracerebroventricular injection of recombinant IL-6 protein at 0.4 μg/day resulted in reduction in food intake per body weight [15] but not at 100–200 ng level [4], suggesting critical impact of IL-6 dose on animal appetite.

Slight, but significant, elevation in body temperature by IL-6 gene transfer (Fig. S1) suggests that an IL-6 mediated reduction in fat mass can be attributed to its action in stimulating thermogenesis and lipid utilization in BAT. Li et al. reported that an increase in central IL-6 levels stimulated the function of BAT and increased Ucp1 expression and heat production [13]. Moreover, transplanted BAT controls mouse body composition and metabolism through an increase in circulating IL-6 [22], indicating that peripheral elevation of IL-6 is capable of exerting its beneficial role. In addition, hydrodynamic injection-mediated IL-6 gene transfer greatly enhanced multiple thermogenic gene expression, including Ucp, Pgc1α, Pgc1β, Cidea and Elovl3 (Fig. 7C). Furthermore, promotion of phosphorylated STAT3, a master molecule in the IL-6 signaling pathway and elevation of PGC-1α and UCP1 proteins in BAT further confirm that IL-6 stimulated BAT function (Fig. 7D–F).

Different from BAT, WAT is the major organ in lipid storage. Sustained IL-6 gene expression resulting from hydrodynamic gene transfer dramatically reduced epic-, sub-, and retro-WAT pad size (Fig. 2), suggesting that IL-6 promotes WAT lipolysis, which contributes to whole body weight loss. In fact, in vitro studies using 3T3-L1 pre-adipocytes and isolated human adipocytes have shown that IL-6...
stimulates lipolysis and glycerol release [23,24]. In vivo human studies further prove that the infusion of recombinant IL-6 increased lipolysis and fat oxidation [25,26]. In line with these studies, our results show that prolonged overexpression of the Il-6 gene significantly enhances transcript levels of Hsl and Atgl in sub-WAT (Fig. 8A), the key enzymes involved in lipolysis. In the meantime, IL-6 also enhanced fatty acid

Fig. 5. Effect of IL-6 gene transfer on hepatic lipid metabolism in obese mice. After HFD-feeding obese mice were sacrificed at the end of 6 weeks after gene transfer, total RNA from the liver was extracted and the relative mRNA levels of selected genes were analyzed by real time PCR. (A) Nuclear receptor genes for metabolic homeostasis, Pparγ1, Pparγ2 and the target genes Cd36, Fabp4 and Mgat1; (B) Genes involved in fatty acid oxidation, Ppara, Cpt1a, Cpt1b and Acox1; and (C) Genes involved in lipogenesis and cholesterol metabolism, Srebp1-c, Acc1, Fas, Scd-1, Hmgcr and Cyp7a1. Each data point represents the mean ± SD (n = 4). *P < 0.05, **P < 0.01 compared to control group.

Fig. 6. IL-6 improves insulin sensitivity and glucose homeostasis in obese mice. (A) Time-dependent blood concentration of glucose upon i.p. injection of glucose (1.5 g/kg); (B) Area under the curve from glucose tolerance test; (C) Time-dependent ratio of glucose concentration upon i.p. injection of insulin (0.75 units/kg); (D) Insulin level at the end of 6 weeks after gene transfer; (E, F) mRNA levels of insulin 1 and insulin 2 in pancreas at the end of 6 weeks after gene transfer; (G) HOMA-IR values. Each data point represents the average ± SD (n = 6). *P < 0.05, **P < 0.01 compared to control animals.
oxidation, as evidenced by increased mRNA levels of Cpt1a and Cpt1b. Moreover, IL-6 increased transcription of thermogenic genes in WAT (Figs. 8A, B), indicating its potential capability in WAT remodeling.

Skeletal muscle is an important organ involved in lipid metabolism. Therefore, we investigated the effect of IL-6 gene transfer on lipid metabolism in skeletal muscle. A Western Blotting analysis showed that prolonged IL-6 gene expression stimulated STAT3 and AMPK activation, consequently enhancing phosphorylation of ACC (Fig. 9A–D). AMPK is well documented to phosphorylate ACC, a rate-limiting step in the conversion of acetyl-CoA to malonyl-CoA. The phosphorylation of ACC inhibits its activity, leading to a decrease in malonyl-CoA and an increase in transferring long-chain fatty acyl-CoA into mitochondria for oxidation. In agreement with these results, other researchers also reported that short-term administration of IL-6 promotes lipid metabolism in rat and human skeletal muscle [27,28]. Overall, these results demonstrate that sustained high levels of IL-6 resulting from hydrodynamic gene delivery stimulates lipolysis in WAT and promotes thermogenesis and lipid metabolism in BAT and skeletal muscle, consequently resulting in improvement of insulin resistance.

Several lines of studies have indicated that IL-6 exerts the protective role in various hepatic diseases. IL-6 stimulates liver regeneration and protects against liver injury [29,30]. Similarly, IL-6 is capable of correcting ethanol-induced hepatic steatosis in IL-6 deficient mice [31]. Moreover, 10 days of subcutaneous IL-6 injection ameliorates the fatty liver in genetic and diet-induced obese mice [32]. Concordance with these reports, IL-6 gene transfer in our study dramatically reduced lipid accumulation as demonstrated by H&E and Oil Red O stained-liver sections and measured hepatic lipid levels (Fig. 4A–E). At the molecular level, IL-6 markedly suppressed mRNA levels of Pparγ and their targeted genes including Cd36, Fabp4 and Mgat1 (Fig. 5A). PPARγ plays an important role in the regulation of lipid metabolism. PPARγ activates adipogenesis and inhibits lipolysis, contributing to the accumulation of triglycerides in adipocytes. The suppression of PPARγ by IL-6 is consistent with the reduction of lipid accumulation seen in our study. Overall, these results provide evidence for the potential therapeutic role of IL-6 in the treatment of insulin resistance and fatty liver disease.
important role in the development of hepatic steatosis. Overexpression of hepatic Pparγ results in exacerbated liver steatosis [33]. Conversely, liver- and hepatocyte-specific Pparγ knockout mice were protected against hepatic lipid accumulation [34–36]. Therefore, the inhibition of hepatic PPARγ pathway is responsible, at least in part, for its beneficial effect on hepatic steatosis. In addition, short-term IL-6 administration has been reported to increase hepatic PPARα and fatty acid oxidation [32]. However, we did not see a change in

Fig. 9. Effect of IL-6 on fat oxidation in skeletal muscle of obese mice. After mice were sacrificed at the end of experiment, the gastrocnemius and soleus muscles were freshly collected and immediately frozen in liquid nitrogen, and then stored at −80 °C. (A) Western Blotting analysis for total and phosphorylated STAT3, AMPK and ACC, as well as GAPDH; (B–D) The ratios of phosphorylated and the native forms of these proteins based on scanning image of (a). *P < 0.05, **P < 0.01 compared to control group (n = 3).

Fig. 10. Effect of Il-6 gene transfer on mRNA levels of macrophage specific marker genes. Mice were sacrificed at the end of experiment. The liver, WAT and BAT tissues were collected and real time PCR was performed to detect mRNA levels of macrophage marker genes. General macrophage marker genes: F4/80 and Cd68; M1-macrophage marker genes: Cd11b, Cd11c, Tnfα, Il-1β, Mcp-1; and M2-macrophage marker genes, Cd163, Cd206, Il-10, Il-4, Il-13, and their receptor genes Il-4rα, Il-13rα1. (A) liver; (B) subWAT; (C) epiWAT and (D) BAT. Each data point represents the average ± SD of 4 animals in each group. *P < 0.05, **P < 0.01 compared to control animals.
**IL-4 and IL-13, and alternatively activated macrophages are involved** to insulin. Recent studies reported that type 2 cytokines, such as generally associated with tissue surveillance and enhanced sensitivity of IL-6 signaling pathway develop systemic insulin resistance[12,39].

Whereas IL-6 transgenic mice displayed higher sensitivity to insulin and their receptor genes (Fig. 10 A-C). Accordingly, obesity-induced hyperinsulinemia and increased expression of pancreatic insulin genes were dramatically reduced (Fig. 6D–F). Similarly, reduction in adiposity and enhanced lipid utilization by IL-6 overexpression also improve glucose homeostasis. In addition, a recent study has shown that IL-6 is capable of stimulating glucagon-like peptide-1 secretion from L-cells and alpha cells, enhancing insulin secretion and reaction [40], which may also contribute to the beneficial effect of IL-6 on glucose metabolism. Taken together, our study supports the notion that IL-6 alleviates obesity-related insulin resistance and improved glucose homeostasis.

Macrophage infiltration is a common feature in HFD-induced obesity. A previous study shows that IFN induces a shift of macrophage phenotype from a M2-polarized state in lean animals to a M1 pro-inflammatory state, characterized by high mRNA level of marker gene such as F4/80 and CD11c, and higher level of pro-inflammatory cytokines [41]. Our results show that IL-6 did not reduce the macrophage infiltration. However, IL-6 markedly enhanced M2 macrophage phenotype, as evidenced by higher mRNA levels of Cd163 and Cd206, anti-inflammatory factor Il-10, stimulator IL-4, Il-13 and their receptor genes (Fig. 10 A-D). M2 macrophages are generally associated with tissue surveillance and enhanced sensitivity to insulin. Recent studies reported that type 2 cytokines, such as IL-4 and IL-13, and alternatively activated macrophages are involved in adaptive thermogenesis and beige cell production, suggesting the important and beneficial role of M2 macrophages in obesity [42–44]. In line with our study, Mauer et al. [45] have shown that a conditionally inactivated IL-6 receptor α in myeloid cells increased systemic inflammation, while administration of IL-6 enhanced IL-4 receptor expression and promoted IL-4 mediated alternative activation of macrophages, which consequently limited obesity-associated chronic inflammation and insulin resistance, as well as LPS-stimulated endotoxemia. Overall, our data suggest that IL-6 treatment in obese mice counterbalances the obesity-related pro-inflammation by elevation of M2 phenotype of macrophages.

In summary, results presented in this study demonstrate that sustained IL-6 gene expression in obese mice, achieved by hydrodynamic gene delivery, enhances lipolysis and thermogenesis, and consequently induces weight loss and diminishes obesity-related fatty liver and insulin resistance. These findings provide direct evidence in support of the potential health benefits of IL-6 in managing obesity and obesity-associated metabolic disorders. Evidently, additional efforts are needed to define the factors that are possibly involved in the process. Additional studies are also needed to assess the potential side effects that IL-6 may induce due to its function as a pro-inflammatory cytokine. Considering the relative smaller BAT depots in human and the difference between mice and human in energy metabolism and thermogenesis, caution should be taken when applying the presented results to humans.

**Supplementary data** to this article can be found online at http://dx.doi.org/10.1016/j.bbadis.2015.01.017.

**Conflict of interest**

The authors declared no conflict of interest.

**Acknowledgements**

We would like to thank Ms. Ryan Fugett for English editing. The study was supported in part by grants from the National Institutes of Health (RO1EB007357 and RO1HL089285).

**References**


